Table 1 Clinical characteristics of LUAD patients
From: A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma
Clinical characteristics of LUAD patients | ||
|---|---|---|
Training set | Validate set | |
No. of patient | 251 | 251 |
Age (mean (SD)) | 64.57 (10.05) | 65.86 (10.04) |
Gender (%) | ||
Male | 123 (49.0) | 109 (43.4) |
Female | 128 (51.0) | 142 (56.6) |
Stage (%) | ||
Stage I | 1 (0.4) | 4 (1.6) |
Stage IA | 73 (29.4) | 57 (23.2) |
Stage IB | 63 (25.4) | 72 (29.3) |
Stage II | 1 (0.4) | 0 (0.0) |
Stage IIA | 22 ( 8.9) | 28 (11.4) |
Stage IIB | 37 (14.9) | 31 (12.6) |
Stage IIIA | 35 (14.1) | 35 (14.2) |
Stage IIIB | 3 ( 1.2) | 7 (2.8) |
Stage IV | 13 ( 5.2) | 12 (4.9) |
Pathologic T (%) | ||
T1 | 38 (15.1) | 27 (10.8) |
T1a | 29 (11.6) | 19 (7.6) |
T1b | 24 (9.6) | 31 (12.4) |
T2 | 78 (31.1) | 82 (32.7) |
T2a | 40 (15.9) | 41 (16.3) |
T2b | 11 (4.4) | 16 (6.4) |
T3 | 23 (9.2) | 22 (8.8) |
T4 | 7 (2.8) | 11 (4.4) |
TX | 1 (0.4) | 2 (0.8) |
Pathologic N (%) | ||
N0 | 164 (65.3) | 162 (64.8) |
N1 | 47 (18.7) | 47 (18.8) |
N2 | 32 (12.7) | 37 (14.8) |
N3 | 1 (0.4) | 1 (0.4) |
NX | 7 (2.8) | 3 (1.2) |
Pathologic M (%) | ||
M0 | 160 (64.3) | 174 69.9) |
M1 | 7 (2.8) | 10 (4.0) |
M1a | 1 (0.4) | 1 (0.4) |
M1b | 4 (1.6) | 1 (0.4) |
MX | 77 (30.9) | 63 (25.3) |
Vital status = Dead (%) | 92 (36.7) | 90 (35.9) |
Race (%) | ||
American indian or alaska native | 1 (0.4) | 0 (0.0) |
Asian | 4 (1.6) | 3 (1.2) |
Black or african american | 26 (10.4) | 26 (10.4) |
Not reported | 26 (10.4) | 28 (11.2) |
White | 194 (77.3) | 194 (77.3) |
Smoke_history = Yes (%) | 88 (35.1) | 99 (39.4) |
OS time (mean) | 890.17 | 926.26 |